Cargando…

Understanding the structure–property relationship of bispecific monoclonal antibodies with Fc site-specific substitutions

Development of novel bispecific antibody (bsAb) platforms offers unprecedented opportunities for a wide variety of therapeutic applications. However, the expression and manufacturing of bsAbs with desired structures can be challenging. Owing to the uniqueness of each bsAb platform, more comprehensiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Bo, Zhao, Yunlong, Adaniya, Stephanie, Fu, Yue, Moon, Youmi, Heftel, Justin, Chen, Shuzhen, Xiao, Hui, Li, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294755/ https://www.ncbi.nlm.nih.gov/pubmed/37357447 http://dx.doi.org/10.1080/19420862.2023.2228006

Ejemplares similares

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
por: Liu, Hongyan, et al.
Publicado: (2017)

Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
por: Escobar-Cabrera, Eric, et al.
Publicado: (2017)

Structural basis of a novel heterodimeric Fc for bispecific antibody production
por: Wei, Hudie, et al.
Publicado: (2017)

Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy.
por: Bosslet, K., et al.
Publicado: (1991)

The application of mathematical modelling to the design of bispecific monoclonal antibodies
por: van Steeg, Tamara J., et al.
Publicado: (2016)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody
por: Kasturirangan, Srinath, et al.
Publicado: (2017)

Characterisation of a humanised bispecific monoclonal antibody for cancer therapy.
por: Bruynck, A., et al.
Publicado: (1993)

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
por: Liu, Liming
Publicado: (2017)

Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma
por: Atallah-Yunes, Suheil Albert, et al.
Publicado: (2022)

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
por: Yu, Shengnan, et al.
Publicado: (2017)

Therapeutic Effect of Ansamitocin Targeted to Tumor by a Bispecific Monoclonal Antibody
por: Okamoto, Kayoko, et al.
Publicado: (1992)

Selection of bispecific antibodies with optimal developability using FcRn‑Ph‑HPLC as an optimized FcRn affinity chromatography method
por: Müller, Thomas, et al.
Publicado: (2023)

Monoclonal antibodies and Fc fragments for treating solid tumors
por: Eisenbeis, Andrea M, et al.
Publicado: (2012)

Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB
por: Stopforth, Richard J., et al.
Publicado: (2016)

Fc-optimized monoclonal antibodies show superior efficacy
por: Flemming, Alexandra
Publicado: (2021)

The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
por: Gogesch, Patricia, et al.
Publicado: (2021)

Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody
por: Wang, Lei, et al.
Publicado: (2013)

Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies
por: Skegro, Darko, et al.
Publicado: (2017)

YEAST SURFACE DISPLAY OF FULL-LENGTH IGG FOR ENGINEERING MONOCLONAL AND BISPECIFIC ANTIBODIES
por: Jiang, Youwei
Publicado: (2023)

Bispecific Engineered Antibody Domains (Nanoantibodies) That Interact Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn
por: Gong, Rui, et al.
Publicado: (2012)

A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
por: Rau, Alexander, et al.
Publicado: (2021)

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
por: Caracciolo, Daniele, et al.
Publicado: (2021)

Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
por: Landgren, Ola, et al.
Publicado: (2023)

Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies
por: Mata-Molanes, Juan J., et al.
Publicado: (2022)

Fc-engineered monoclonal antibodies to reduce off-target liver uptake
por: Mangeat, Tristan, et al.
Publicado: (2023)

Monoclonal Antibody Preparation and Epitope Identification for Brucella melitensis Elongation Factor Tu
por: Zhao, Ningning, et al.
Publicado: (2019)

Engineering the hinge region of human IgG1 Fc-fused bispecific antibodies to improve fragmentation resistance
por: Suzuki, Saori, et al.
Publicado: (2018)

Antibody therapy: Substitution-immunomodulation -monoclonal immunotherapy
por: Mehra, Narinder K.
Publicado: (2019)

EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies
por: Cooke, Heather A., et al.
Publicado: (2018)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy
por: Turini, Marc, et al.
Publicado: (2014)

Modulation of protein A binding allows single-step purification of mouse bispecific antibodies that retain FcRn binding
por: Zwolak, Adam, et al.
Publicado: (2017)

Soluble Expression of Fc-Fused T Cell Receptors Allows Yielding Novel Bispecific T Cell Engagers
por: Zhao, Wen-Bin, et al.
Publicado: (2021)

Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models
por: Valente, Delphine, et al.
Publicado: (2020)

Human T lymphocyte subpopulations defined by Fc receptors and monoclonal antibodies. A comparison
Publicado: (1980)

The state of the art of bispecific antibodies for treating human malignancies
por: Wang, Shuhang, et al.
Publicado: (2021)

Long-term passaging of pseudo-typed SARS-CoV-2 reveals the breadth of monoclonal and bispecific antibody cocktails
por: Ma, Hang, et al.
Publicado: (2023)

Modeling bispecific monoclonal antibody interaction with two cell membrane targets indicates the importance of surface diffusion
por: Sengers, Bram G., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_agpgn45jppjuimeolu1fprcl38